Latest
Amgen teams up with Merck on melanoma treatments
Thousand Oaks-based Amgen and pharmaceutical giant Merck are working together to evaluate the safety and effectiveness of combined treatments for melanoma patients.
Latest
Amgen profits hit $5B, beat expectations
The biotech company recorded earnings per share of $7.60, well above the $7.46 expected by a survey of 27 analysts by Thomson Reuters.
Latest
Amgen reports positive trial results for high-cholesterol treatment
The portion of Amgen’s Phase 3 trial of evolocumab that evaluated patients with high cholesterol who cannot tolerate statins has met goals related to percent reduction of low-density lipoprotein cholesterol.
Latest
Amgen’s chief financial officer to depart
Chief Financial Officer Jonathan M. Peacock is leaving Amgen to pursue broader career opportunities, the company announced. Michael A. Kelly has been named acting CFO.
